Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Tuberous Sclerosis 2

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × ganaxolone × Clear all
NCT05604170 2025-10-01

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Terminated
117 enrolled 11 charts

Tuberous Sclerosis

NCT05323734 2025-07-11

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Completed
129 enrolled 13 charts

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡